The 'nightmare' superbug resistant to our strongest antibiotics

A cousin of E. coli has somehow gained the ability to fend off our most powerful drugs, and now the CDC is stepping in

"CRE are a nightmare bacteria. Our strongest antibiotics don't work, and patients are left with potentially untreatable infections."
(Image credit: ThinkStock/F1online)

A stubborn bacteria is spreading in U.S. hospitals, which could prove deadly for patients with already-weakened immune systems. And now the Centers for Disease Control and Prevention are stepping in, calling for medical professionals across the country to buckle down with stringent preventative measures.

The lethal bacteria is called carbapenem-resistant enterobacteriaceae — CRE for short. Unlike other bacterium in the enterobacteriaceae family (which includes E. coli), CRE has somehow become resistant to a powerful line of antibiotics called carbapenems, which are some of the strongest drugs we have, and are often used as a last line of defense.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Chris Gayomali is the science and technology editor for TheWeek.com. Previously, he was a tech reporter at TIME. His work has also appeared in Men's Journal, Esquire, and The Atlantic, among other places. Follow him on Twitter and Facebook.